Chief Executive of Gain Therapeutics. Leading a biotech company engaged in the development of a potentially disease-modifying therapy for the treatment of neurodegenerative diseases. Hoping to unlock new treatments for difficult to treat disorders with the SEE-Tx supercomputer-driven, drug discovery platform targeting allosteric binding sites.